High-titer lentiviral vectors stimulate fetal calf serum-specific human CD4 T-cell responses: Implications in human gene therapy

Gene Therapy

Volumn 16, Issue 6, 2009, Pages 788-795

  Bao, L ^a,b   Guo, H ^a,b   Huang, X ^a,b   Tammana, S ^c   Wong, M ^a,b   McIvor, R S ^a,b   Zhou, X ^a,b,c  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DR1 ANTIGEN; HLA DR4 ANTIGEN; INFLUENZA VIRUS HEMAGGLUTININ; LENTIVIRUS VECTOR; LEUKOCYTE ANTIGEN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL BASED GENE THERAPY; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; DILUTION; FETAL CALF SERUM; GENE TRANSFER; HUMAN; HUMAN CELL; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANTIGEN PRESENTATION; CATTLE; CD4-POSITIVE T-LYMPHOCYTES; CELL CULTURE TECHNIQUES; CELL LINE; CULTURE MEDIA; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, MHC CLASS II; GENETIC VECTORS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HLA ANTIGENS; HUMANS; LENTIVIRUS; PLASMIDS; TRANSDUCTION, GENETIC;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 67349212906     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2009.34     Document Type: Article

References (32)

1. Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, Leventhal L et al. Neurodegeneration. Science 2000; 290: 767-773.
2. Consiglio A, Quattrini A, Martino S, Bensadoun JC, Dolcetta D, Trojani A et al. In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: Correction of neuropathology and protection against learning impairments in affected mice. Nat Med 2001; 7: 310-316.
3. Azzouz M, Le T, Ralph GS, Walmsley L, Monani UR, Lee DC et al. Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy. J Clin Invest 2004; 114: 1726-1731.
4. Levine BL, Humeau LM, Boyer J, MacGregor RR, Rebello T, Lu X et al Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci USA 2006; 103: 17372-17377.
5. Naldini L, Blomer U, Gage FH, Trono D, Verma IM. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA 1996; 93: 11382-11388.
6. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-267.
7. Saenz DT, Poeschla EM. FIV: From lentivirus to lentivector. J Gene Med 2004; 6: S95-104.
8. Blomer U, Naldini L, Kafri T, Trono D, Verma IM, Gage FH. Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J Virol 1997; 71: 6641-6649.
9. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D et al. A third- generation lentivirus vector with a conditional packaging system. J Virol 1998; 72: 8463-8471.
10. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotech 1997; 15: 871-875.
11. Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, Naldini L et al Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 1998; 72: 9873-9880.
12. van Lunzen J, Glaunsinger T, Stahmer I, von Baehr V, Baum C, Schilz A et al. Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus. Mol Ther 2007; 15: 1024-1033.
13. Gruber A, Kan-Mitchell J, Kuhen KL, Mukai T, Wong-Staal F. Dendritic cells transduced by multiply deleted HIV-1 vectors exhibit normal phenotypes and functions and elicit an HIV-specific cytotoxic T-lymphocyte response in vitro. Blood 2000; 96: 1327-1333.
14. Dyall J, Latouche J-B, Schnell S, Sadelain M. Lentivirus-transduced human monocyte-derived dendritic cells efficiently stimulate antigen-specific cytotoxic T lymphocytes. Blood 2001; 97: 114-121.
15. Firat H, Zennou V, Garcia-Pons F, Ginhoux F, Cochet M, Danos O et al Use of a lentiviral flap vector for induction of CTL immunity against melanoma. Perspectives for immunotherapy. J Gene Med 2002; 4: 38-45.
16. Breckpot K, Dullaers M, Bonehill A, Van Meirvenne S, Heirman C, De Greef C et al. Lentivirally transduced dendritic cells as a tool for cancer immunotherapy. J Gene Med 2003; 5: 654-667.
17. Lizee G, Gonzales MI, Topalian SL. Lentivirus vector-mediated expression of tumor-associated epitopes by human antigen presenting cells. Hum Gene Ther 2004; 15: 393-404.
18. Chen X, Wang B, Chang L-J. Induction of primary anti-HIV CD4 and CD8 T cell responses by dendritic cells transduced with self-inactivating lentiviral vectors. Cell Immunol 2006; 243: 10-18.
19. Breckpot K, Aerts JL, Thielemans K. Lentiviral vectors for cancer immunotherapy: Transforming infectious particles into therapeutics. Gene Therapy 2007; 14: 847-862.
20. Wu TC, Guarnieri FG, Staveley-O'Carroll KF, Viscidi RP, Levitsky HI, Hedrick L et al. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci USA 1995; 92: 11671-11675.
21. Riddell SR, Elliott M, Lewinsohn DA, Gilbert MJ, Wilson L, Manley SA et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 1996; 2: 216-223.
22. Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997; 276: 1719-1724.
23. Selvaggi TA,Walker RE, Fleisher TA. Development of antibodies to fetal calf serum with arthus-like reactions in human immunodeficiency virus-infected patients given syngeneic lymphocyte infusions. Blood 1997; 89: 776-779.
24. Tuschong L, Soenen SL, Blaese RM, Candotti F, Muul LM. Immune response to fetal calf serum by two adenosine deaminase-deficient patients after T cell gene therapy. Hum Gene Ther 2002; 13: 1605-1610.
25. Mackensen A, Drager R, Schlesier M, Mertelsmann R, Lindemann A. Presence of IgE antibodies to bovine serum albumin in a patient developing anaphylaxis after vaccination with human peptide-pulsed dendritic cells. Cancer Immunol Immunother 2000; 49: 152-156.
26. Baekelandt V, Claeys A, Eggermont K, Lauwers E, De Strooper B, Nuttin B et al. Characterization of lentiviral vector-mediated gene transfer in adult mouse brain. Hum Gene Ther 2002; 13: 841-853.
27. Baekelandt V, Eggermont K, Michiels M, Nuttin B, Debyser Z. Optimized lentiviral vector production and purification procedure prevents immune response after transduction of mouse brain. Gene Therapy 2003; 10: 1933-1940.
28. Wang RF, Wang X, Atwood AC, Topalian SL, Rosenberg SA. Cloning genes encoding MHC class II-restricted antigens: Mutated CDC27 as a tumor antigen. Science 1999; 284: 1351-1354.
29. Amendola M, Venneri MA, Biffi A, Vigna E, Naldini L. Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters. Nat Biotechnol 2005; 23: 108-116.
30. Zhou X, Cui Y, Huang X, Yu Z, Thomas AM, Ye Z et al. Lentivirus-mediated gene transfer and expression in established human tumor antigen-specific cytotoxic T cells and primary unstimulated T cells. Hum Gene Ther 2003; 14: 1089-1105.
31. Tiscornia G, Singer O, Verma IM. Production and purification of lentiviral vectors. Nat Protocols 2006; 1: 241-245.
32. Riddell SR, Greenberg PD. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J Immunol Methods 1990; 128: 189-201.